Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Predicting survival in hepatitis B.

Literature DB >> 16227355

Predicting survival in hepatitis B.

M Sherman¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2005 PMID： 16227355 PMCID： PMC1774728 DOI： 10.1136/gut.2005.071332

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

× No keyword cloud information.

23 in total

1. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins.

Authors: George Marx; Steven R Martin; Jean-Francois Chicoine; Fernando Alvarez
Journal: J Infect Dis Date: 2002-07-17 Impact factor: 5.226

2. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.

Authors: M F Yuen; C K Hui; C C Cheng; C H Wu; Y P Lai; C L Lai
Journal: Hepatology Date: 2001-07 Impact factor: 17.425

3. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice.

Authors: H L-Y Chan; S W-C Tsang; Y Hui; N W-Y Leung; F K-L Chan; J J-Y Sung
Journal: J Viral Hepat Date: 2002-11 Impact factor: 3.728

4. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

Authors: S W Schalm; J Heathcote; J Cianciara; G Farrell; M Sherman; B Willems; A Dhillon; A Moorat; J Barber; D F Gray
Journal: Gut Date: 2000-04 Impact factor: 23.059

5. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.

Authors: B C Song; D J Suh; H C Lee; Y H Chung; Y S Lee
Journal: Hepatology Date: 2000-10 Impact factor: 17.425

6. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

Authors: R J Colonno; E V Genovesi; I Medina; L Lamb; S K Durham; M L Huang; L Corey; M Littlejohn; S Locarnini; B C Tennant; B Rose; J M Clark
Journal: J Infect Dis Date: 2001-10-29 Impact factor: 5.226

7. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

Authors: Yao-Shih Hsu; Rong-Nan Chien; Chau-Ting Yeh; I-Shyan Sheen; Hung-Yi Chiou; Chia-Ming Chu; Yun-Fan Liaw
Journal: Hepatology Date: 2002-06 Impact factor: 17.425

8. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.

Authors: M-F Yuen; H-J Yuan; D K-H Wong; J C-H Yuen; W-M Wong; A O-O Chan; B C-Y Wong; K-C Lai; C-L Lai
Journal: Gut Date: 2005-05-04 Impact factor: 23.059

9. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

Authors: Maurizia Rossana Brunetto; Filippo Oliveri; Barbara Coco; Gioacchino Leandro; Piero Colombatto; Juliana Monti Gorin; Ferruccio Bonino
Journal: J Hepatol Date: 2002-02 Impact factor: 25.083

5. The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis.

Authors: Qiao-Ling Xie; Ying Zhu; Ling-Hong Wu; Lin-Lin Fu; Yan Xiang
Journal: PLoS One Date: 2015-07-30 Impact factor: 3.240

5 in total

Predicting survival in hepatitis B.

1. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins.

2. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.

3. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice.

4. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

5. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.

6. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

7. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

8. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.

9. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

10. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.

Review 1. Chronic hepatitis B--who should be treated?

2. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

3. Histological changes in chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal.

Review 4. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.

5. The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis.